Association of IL-10 and TNFα genotypes with ANCA appearance in ulcerative colitis

Clinical Immunology

Volumn 122, Issue 1, 2007, Pages 108-114

  Castro Santos, Patricia ^a   Suarez, Ana ^b   Mozo, Lourdes ^a   Gutierrez, Carmen ^a,b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

ANCA; Cytokine polymorphisms; IL 10; Inflammatory bowel disease; TNF

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INTERLEUKIN 10; MERCAPTOPURINE; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ALLELE; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SCHOOL CHILD; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CHILD; COLITIS, ULCERATIVE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENOTYPE; GOBLET CELLS; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845904388     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.09.010     Document Type: Article

References (44)

1. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. 3 (2003) 521
2. Peeters M., Joosens M., Vermeire S., Vlientick R., Bossuyt X., and Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am. J. Gastroenterol. 96 (2001) 730
3. Conrad K., Schmechta H., Klafki A., Lobeck G., Uhlig H., Gerdi S., and Henker J. Serological differentiation of inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 14 (2002) 129
4. Joosens S., Reinisch W., Vermeire S., Sendid B., Poulain D., Peeters M., Geboes K., Bossuyt X., Vandewalle P., and Colonbel J. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 122 (2002) 1242
5. Vidrich A., Lee J., James E., Cobb L., and Targan S. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J. Clin. Immunol. 15 (1995) 293
6. Billing P., Tahir S., Clfin B., Gagne G., Cobb L., Targan S., and Vidrich A. Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am. J. Pathol. 147 (1995) 979
7. Eggena M., Cohavy O., Parseghian M., Hamkalo B., Clemens D., Targan S., Gordon L., and Braun J. Identification of histone 1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. J. Autoimmun. 14 (2000) 83
8. Sobajima J., Ozaki S., Uesugi S., Osakada H., Shirakawa H., Yoshida M., and Nakao K. Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) directed against HGM1 and HGM2 in ulcerative colitis (UC). Clin. Exp. Immunol. 111 (1998) 402
9. Sobajima J., Ozaki S., Uesugi H., Osakada H., Inoue M., Fukuda Y., Shirakawa H., Yoshida M., Rokuhara A., Imai H., Kiyosawa K., and Nakao K. High mobility group (HMG) non histone chromosomal proteins HGM1 and HGM2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis. Gut 44 (1999) 867
10. Terjung B., Spengler U., Sauerbruch T., and Worman H. "Atypical pANCA" in IBD and hepatobiliary disorders react with a 50 kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 119 (2000) 310
11. Vecchi M., Bianchi M., Sinico R., Radice A., Meucci G., Torgano G., Omodei P., Forzenigo L., Landoni M., and Arrigoni M. Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: sensitivity, specificity and recognition of putative antigens. Digestion 55 (1994) 34
12. Vecchi M., Bianchi M., Calabresi C., Meucci G., Tatarella M., and de Franchis R. Long-term observation of the perinuclear anti-neutrophil cytoplasmic antibody status in ulcerative colitis patients. Scand. J. Gastroenterol. 33 (1998) 170
13. Fleshner P., Vasiliauskas E., Kam L., Fleshner N., Gaiennie J., Abreu-Martin M., and Targan S. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 49 (2001) 671
14. Boerr L., Sambuelli A., and Katz S. Clinical heterogeneity of ulcerative colitis in relation to frequency of pANCA reactivity. Gastroenterology 108 (1995) A785
15. Sandborn W., Landers C., Tremaine W., and Targan S. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin. Proc. 71 (1996) 431
16. Seibold F., Weber P., Jenss H., and Wiedmann K. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. Gut 32 (1991) 1192
17. Folwaczny C., Noehl N., Tschöp K., Endres S., Heldwein W., Loeschke K., and Fricke H. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterology 113 (1997) 101
18. Shanahan F., Duerr R., Rotter J., Yang H., Sutherland L., and McElree C. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology 103 (1992) 456
19. Folwaczny C., Noehl N., Endres S., Loeschke K., and Fricke H. Antineutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel disease. Scand. J. Gastroenterol. 33 (1998) 523
20. Seibold F., Slametschka D., Gregor M., and Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 107 (1994) 532
21. Suarez A., Castro P., Alonso R., Mozo L., and Gutierrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 75 (2003) 711
22. Westendorp R., Langermans J., Huizinga T., Elouali A., Verweij C., Boomsma D., and Vanderbroucke J. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349 (1997) 170
23. Turner D., Williams D., and Sankaran D. An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet. 24 (1997) 1
24. Wilson A., Symons J., and Mcdowell T. Effects of a polymorphism in the human necrosis factor a promoter on transcriptional activation. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 3195
25. Kroeger K., Steer J., Joyce D., and Abraham L. Effects of stimulus and cell type on the expression of the - 308 tumour necrosis factor promoter polymorphism. Cytokine 12 (2000) 110
26. Gottenberg J., Busson M., Loiseau P., Dourche M., Cohen-Solal J., Lepage V., Charron D., Miceli C., Sibilia J., and Maritte X. Association of transforming growth factor b1 and tumour necrosis factor a in patients with primary Sjögren's syndrome. Arthritis Rheum. 50 (2004) 570
27. Lazarus M., Hajeer A., Turner D., Sinnott P., Wortington J., Ollier W., and Hutchinson I. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J. Rheumatol. 24 (1997) 2314
28. Hahn-Zoric M., Hytonen A., Hanson L., Nilsson L., and Padyukov L. Association of - 1087 IL-10 and - 308 TNFA gene polymorphisms with serological markers of coeliac disease. J. Clin. Immunol. 23 (2003) 291
29. Lennard-Jones J. Classification of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 170 (1989) 2
30. Carter M., Lobo A., and Travis S & IBD section of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 53 (2004) v1
31. Castro-Santos P., Suarez A., López-Rivas L., Mozo L., and Gutierrez C. TNFa and IL-10 gene polymorphisms in inflammatory bowel disease. Association of - 1082 AA low producer IL-10 genotype with steroid dependency. Am. J. Gastroenterol. 101 (2006) 1
32. Sandborn W. Serologic markers in inflammatory bowel disease: state of the art. Rev. Gastroenterol. Disord. 4 (2004) 167
33. Roussomoustakaki M., Satsangi J., Welsh K., Louis E., Fanning G., Targan S., Landeers C., and Jewell D. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 112 (1997) 1845
34. Yang H., Rotter J., Toyoda H., Landers C., Tyran D., McElree C., and Targan S. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J. Clin. Invest. 92 (1993) 1080
35. Satsangi J., Landers C., Welsh K., Koss K., Targan S., and Jewell D. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm. Bowel dis. 4 (1998) 18
36. Hirv K., Seyfarth M., Uibo R., Kull K., Salupere R., Latza U., and Rink L. Polymorphisms in tumour necrosis factor and adhesion molecule genes in patients with inflammatory bowel disease: associations with HLA-DR and DQ alleles and subclinical markers. Scand. J. Gastroenterol. 34 (1999) 1025
37. Rood M., van Krugten M., Zanelli E., van der Linden M., Keijers V., Schreuder G., Verduyn W., Westendorp R., de Vries R., Breedveld F., Verweij C., and Huizinga T. TNF - 308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum. 43 (2000) 129
38. Bouma G., Poen A., Garcia-González M., Schreuder G., Felt-Bersma R., Meuwissen S., and Pena A. HLA-DRB1*03, but not the TNFA - 308 promoter gene polymorhism, confers protection against fistulising Crohn's disease. Immunogenetics 47 (1998) 451
39. Deem R., Shanahan F., and Targan S. Triggered mucosal T cells release tumour necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells. Clin. Exp. Immunol. 83 (1991) 79
40. Bruewer M., Luegering A., Kucharzik T., Parkos C., Madara J., Hopkins A., and Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J. Immunol. 171 (2003) 6164
41. Van Deventer S. Tumour necrosis factor and Crohn's disease. Gut 40 (1997) 443
42. Moore K., de Waal Malefyt R., Coffman R., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19 (2001) 683
43. Hara M., Kingsley C., Niimi M., Read S., Turvey S., Bushell A., Morris P., Powrie F., and Wood K. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J. Immunol. 166 (2001) 3789
44. Seibold F., Brandwein S., Simpson S., Terhorst C., and Elson C. P-ANCA represents a cross-reactivity to enteric bacterial antigens. J. Clin. Immunol. 18 (1998) 153